InvestigationalAmylin + GLP-1 combinationWeight loss
Cagrilintide + semaglutide (CagriSema)
CagriSema is Novo Nordisk's investigational combination of cagrilintide (an amylin analog) and semaglutide, tested in the REDEFINE phase 3 trials.
What is Cagrilintide + semaglutide?
CagriSema is Novo Nordisk's investigational combination of cagrilintide (an amylin analog) and semaglutide, tested in the REDEFINE phase 3 trials. Cagrilintide + semaglutide (CagriSema) is an investigational compound: it has been studied in clinical trials but has no FDA approval.
Key takeaways
- Cagrilintide + semaglutide (CagriSema) is an investigational compound: it has been studied in clinical trials but has no FDA approval.
- PubMed indexes 27 papers on Cagrilintide + semaglutide (6 tagged as clinical trials) as of October 19, 2026.
- 5 vendors in our directory listed Cagrilintide + semaglutide in their public catalog on October 19, 2026.
What is in this blend?
The blend combines 2 compounds. No published study has tested this combination as a product; each component's evidence is separate.
Regulatory & access status
Cagrilintide + semaglutide (CagriSema) is an investigational compound: it has been studied in clinical trials but has no FDA approval.
Sellers that market unapproved peptides for human use can receive FDA warning letters; our vendor directory links any letter we found on fda.gov.
How much research exists on Cagrilintide + semaglutide (CagriSema)?
PubMed indexes 27 papers mentioning Cagrilintide + semaglutide (CagriSema) in the title or abstract, 27 of them from the last five years and 6 tagged as clinical trials (search run October 19, 2026; repeat the search).
Most relevant recent papers
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. — N Engl J Med, 2025 · clinical trial
- Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. — Lancet Diabetes Endocrinol, 2026 · clinical trial
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. — N Engl J Med, 2025 · clinical trial
- Beyond weight loss: multisystem benefits of obesity medications. — Lancet Diabetes Endocrinol, 2026 · review
- Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. — Lancet, 2026 · clinical trial
- Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. — Endocr Rev, 2026 · review
What the evidence does not show
- Paper counts measure research attention, not whether Cagrilintide + semaglutide works or is safe.
- No FDA review of any "research use only" product's identity, purity, sterility or dose.
- No study of this specific blend as sold.
Research suppliers that list Cagrilintide + semaglutide
5 vendors in our directory listed a product matching Cagrilintide + semaglutide in their public catalog on October 19, 2026. Listed alphabetically; a listing is not an endorsement. Research use only.
Prices per mg, where we could verify them, are on our price comparison.
Cagrilintide + semaglutide reconstitution math
Lab arithmetic only, not dosing guidance: use the peptide calculator to turn a vial size and diluent volume into a concentration.
Cagrilintide + semaglutide FAQ
Is Cagrilintide + semaglutide FDA-approved?
Cagrilintide + semaglutide (CagriSema) is an investigational compound: it has been studied in clinical trials but has no FDA approval.
Is Cagrilintide + semaglutide safe?
Safety data come from the published studies listed on this page; read them in full. Products sold as "research use only" have no FDA review of their purity, sterility or dose.
How much research is there on Cagrilintide + semaglutide?
PubMed indexes 27 papers on Cagrilintide + semaglutide (6 tagged as clinical trials) as of October 19, 2026.
Who sells Cagrilintide + semaglutide?
BioGenix Peptides, Bulk Peptide Supply, Liberty Peptides, Modern Aminos, Polaris Peptides listed it on their public catalogs when we checked; a listing is not an endorsement.
Related compounds
SemaglutideLiraglutideTirzepatideAICARL-carnitineMOTS-cBPC-157 + TB-500 blendTri-heal blendAll weight loss & glp-1All blends & stacks